These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1838041)

  • 41. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
    Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
    [No Abstract]   [Full Text] [Related]  

  • 42. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
    Greene DA; Arezzo JC; Brown MB
    Neurology; 1999 Aug; 53(3):580-91. PubMed ID: 10449124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
    Nishimura C; Saito T; Ito T; Omori Y; Tanimoto T
    Diabetologia; 1994 Mar; 37(3):328-30. PubMed ID: 8174849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorbitol metabolism in the retina, optic nerve, and sural nerve of diabetic rats treated with an aldose reductase inhibitor.
    Naeser P; Brolin SE; Eriksson UJ
    Metabolism; 1988 Dec; 37(12):1143-5. PubMed ID: 3143049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Childhood diabetic neuropathy: a clinical and electrophysiological study.
    el Bahri-Ben Mrad F; Gouider R; Fredj M; Ben Becher S; Mrad-Mazigh S; Mrabet A
    Funct Neurol; 2000; 15(1):35-40. PubMed ID: 10842758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic analysis of aldose reductase in diabetic complications.
    Chung SS; Chung SK
    Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(4):242-6. PubMed ID: 1482782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased erythrocyte aldose reductase activity in type 1 diabetic patients.
    Hamada Y; Kito R; Raskin P
    Diabet Med; 1991 Apr; 8(3):226-31. PubMed ID: 1828737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians.
    Petrovic MG; Peterlin B; Hawlina M; Petrovic D
    J Diabetes Complications; 2005; 19(2):70-3. PubMed ID: 15745835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aldose reductase inhibitors and cataract.
    Crabbe MJ
    Int Ophthalmol; 1991 Jan; 15(1):25-36. PubMed ID: 1901300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus.
    Lee SS; Han HS; Kim H
    Pediatr Diabetes; 2010 Dec; 11(8):521-8. PubMed ID: 20723100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aldose reductase inhibitors and diabetic complications.
    Tomlinson DR; Willars GB; Carrington AL
    Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on clinical markers of diabetes mellitus. 6. Red blood cell sorbitol and diabetic complications.
    Hatano M; Katsu K; Fuda H; Taguchi H; Aro T; Hiyoshi S; Sugiura M; Maruyama S
    Meikai Daigaku Shigaku Zasshi; 1990; 19(2):230-3. PubMed ID: 2134294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.